Following a €1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised €18.5m in a Series A round led by Advent France Biotechnology and Medicxi.

NorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate.

4SC AG and Merck KgaA  have signed a supply agreement to start clinical tests of Merck’s checkpoint blocker avelumab plus 4SC’s HDAC I blocker domatinostat.

Despite the threat of a looming climate catastrophe, low oil prices and giant industrial conglomerates addicted to fossil resources continue to stifle industrial biotechnology products and innovation. The European Biotechnology Network is now providing a foot up for companies that want to help themselves by launching three very different projects aimed at pushing the bioeconomy forward.

Mutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
 

Critical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.

Norwegian biopharma company Zelluna Immunotherapy appointed erstwhile CSO Namir Hassan as Chief Executive Officer.

Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients

Creoptix AG, a Switzerland-based company focused on next-generation bioanalytical instruments, has named Line Stigen Raquet as Chief Executive Officer.

Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds.